TY - JOUR
T1 - Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program
T2 - Updated results of the multicenter consecutive GITMO trial
AU - Ladetto, M.
AU - Vallet, S.
AU - Benedetti, F.
AU - Vitolo, U.
AU - Martelli, M.
AU - Callea, V.
AU - Patti, C.
AU - Coser, P.
AU - Perrotti, A.
AU - Sorio, M.
AU - Boccomini, C.
AU - Pulsoni, A.
AU - Stelitano, C.
AU - Scimè, R.
AU - Boccadoro, M.
AU - Rosato, R.
AU - De Marco, F.
AU - Zanni, M.
AU - Corradini, P.
AU - Tarella, C.
PY - 2006/10
Y1 - 2006/10
N2 - This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged ≤60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.
AB - This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged ≤60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=33750096460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750096460&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404346
DO - 10.1038/sj.leu.2404346
M3 - Article
C2 - 16932351
AN - SCOPUS:33750096460
VL - 20
SP - 1840
EP - 1847
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 10
ER -